Patents by Inventor Mark Welch

Mark Welch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR TREATING CONGENITAL SUCRASE-ISOMALTASE DEFICIENCY
    Publication number: 20250243475
    Abstract: Disclosed are recombinant mutant isomaltase enzymes, and pharmaceutical compositions comprising an isomaltase enzyme, e.g., a recombinant mutant isomaltase enzyme, and an optional invertase enzyme. The enzymes and compositions can be used, among other things, to treat congenital sucrase-isomaltase deficiency (CSID).
    Type: Application
    Filed: July 13, 2023
    Publication date: July 31, 2025
    Inventors: Sridhar Govindarajan, Mark Welch, Alexey Margolin
  • DNA VECTORS, TRANSPOSONS AND TRANSPOSASES FOR EUKARYOTIC GENOME MODIFICATION
    Publication number: 20250043235
    Abstract: The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.
    Type: Application
    Filed: October 21, 2024
    Publication date: February 6, 2025
    Applicant: DNA TWOPOINTO INC.
    Inventors: Jeremy Minshull, Mark Welch, Sridhar Govindrajan, Maggie Lee, Kate Caves, Jon Ness
  • ENGINEERED LIPASE ENZYMES, MANUFACTURE AND USE THEREOF
    Publication number: 20240392270
    Abstract: Provided are engineered lipase enzymes, methods of making such engineered lipases, dosage forms containing such engineered lipases and, methods of using such engineered lipases for treating diseases or disorders associated with reduced ability to digest and/or absorb triglycerides (fats).
    Type: Application
    Filed: September 30, 2022
    Publication date: November 28, 2024
    Inventors: Robert Gallotto, Alexey Margolin, Hugh Wight, Jack Greene, Mark Welch, Claes Gustafsson, Sridhar Govindarajan
  • DNA vectors, transposons and transposases for eukaryotic genome modification
    Patent number: 12122995
    Abstract: The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: October 22, 2024
    Assignee: DNA TWOPOINTO INC.
    Inventors: Jeremy Minshull, Mark Welch, Sridhar Govindrajan, Maggie Lee, Kate Caves, Jon Ness
  • DNA vectors, transposons and transposases for eukaryotic genome modification
    Patent number: 12054702
    Abstract: The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: August 6, 2024
    Assignee: DNA TWOPOINTO INC.
    Inventors: Jeremy Minshull, Mark Welch, Sridhar Govindrajan, Maggie Lee, Kate Caves, Jon Ness
  • Epimerase enzymes and their use
    Patent number: 11859228
    Abstract: This disclosure provides epimerase enzymes useful for commercial scale production of allulose from fructose. The disclosed enzymes (“epimerase variants”) are variants of Burkholderia multivorans CGD1 xylose isomerase engineered to have improved catalytic activity of about 1.5- to 2-fold compared with the parent enzyme.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: January 2, 2024
    Assignee: ARCHER DANIELS MIDLAND COMPANY
    Inventors: William Schroeder, Padmesh Venkitasubramanian, Sridhar Govindarajan, Mark Welch
  • DNA VECTORS, TRANSPOSONS AND TRANSPOSASES FOR EUKARYOTIC GENOME MODIFICATION
    Publication number: 20220282260
    Abstract: The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.
    Type: Application
    Filed: May 18, 2022
    Publication date: September 8, 2022
    Inventors: Jeremy Minshull, Mark Welch, Sridhar Govindrajan, Maggie Lee, Kate Caves, Jon Ness
  • EPIMERASE ENZYMES AND THEIR USE
    Publication number: 20220145344
    Abstract: This disclosure provides epimerase enzymes useful for commercial scale production of allulose from fructose. The disclosed enzymes (“epimerase variants”) are variants of Burkholderia multivorans CGD1 xylose isomerase engineered to have improved catalytic activity of about 1.5- to 2-fold compared with the parent enzyme.
    Type: Application
    Filed: August 7, 2019
    Publication date: May 12, 2022
    Applicant: Archer Daniels Midland Company
    Inventors: William Schroeder, Padmesh Venkitasubramanian, Sridhar Govindarajan, Mark Welch
  • Anti-Abeta Antibodies
    Publication number: 20220089762
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Application
    Filed: October 25, 2021
    Publication date: March 24, 2022
    Inventors: Michael SKOV, Tarlochan S. NIJJAR, Sridhar GOVINDARAJAN, Tom PURCELL, Mark WELCH, Frédérique BARD, Robin BARBOUR, Wagner ZAGO
  • Anti-Abeta Antibodies
    Publication number: 20220049009
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Application
    Filed: July 23, 2021
    Publication date: February 17, 2022
    Inventors: Michael SKOV, Tarlochan S. NIJJAR, Sridhar GOVINDARAJAN, Tom PURCELL, Mark WELCH, Frédérique BARD, Robin BARBOUR, Wagner ZAGO
  • Anti-Abeta Antibodies
    Publication number: 20220041700
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Application
    Filed: October 25, 2021
    Publication date: February 10, 2022
    Inventors: Michael SKOV, Tarlochan S. NIJJAR, Sridhar GOVINDARAJAN, Tom PURCELL, Mark WELCH, Frédérique BARD, Robin BARBOUR, Wagner ZAGO
  • Anti-Abeta Antibodies
    Publication number: 20220041699
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Application
    Filed: October 25, 2021
    Publication date: February 10, 2022
    Inventors: Michael SKOV, Tarlochan S. NIJJAR, Sridhar GOVINDARAJAN, Tom PURCELL, Mark WELCH, Frédérique BARD, Robin BARBOUR, Wagner ZAGO
  • Anti-Abeta Antibodies
    Publication number: 20220041701
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Application
    Filed: October 25, 2021
    Publication date: February 10, 2022
    Inventors: Michael SKOV, Tarlochan S. NIJJAR, Sridhar GOVINDARAJAN, Tom PURCELL, Mark WELCH, Frédérique BARD, Robin BARBOUR, Wagner ZAGO
  • Nucleic acids and vectors for regulated target gene expression in methanotrophic bacteria
    Patent number: 11041159
    Abstract: The present disclosure provides nucleic acids and vectors for use with methanotrophic bacteria. Related host cells and methods for using such nucleic acids and vectors for expressing polypeptides or other genetic manipulation of methanotrophic bacteria are also provided.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: June 22, 2021
    Assignee: Calysta, Inc.
    Inventors: Renee M. Saville, Joshua Silverman, Jeremy Minshull, Jon Edward Ness, Effendi Leonard, Jana Stumpe, Mark Welch
  • DNA VECTORS, TRANSPOSONS AND TRANSPOSASES FOR EUKARYOTIC GENOME MODIFICATION
    Publication number: 20210139919
    Abstract: The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.
    Type: Application
    Filed: January 15, 2021
    Publication date: May 13, 2021
    Applicant: DNA TWOPOINTO INC.
    Inventors: Jeremy Minshull, Mark Welch, Sridhar Govindrajan, Maggie Lee, Kate Caves, Jon Ness
  • DNA vectors, transposons and transposases for eukaryotic genome modification
    Patent number: 10927384
    Abstract: The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: February 23, 2021
    Assignee: DNA TWOPOINTO INC.
    Inventors: Jeremy Minshull, Mark Welch, Sridhar Govindrajan, Maggie Lee, Kate Caves, Jon Ness
  • Recombinant uricase enzyme
    Patent number: 10815461
    Abstract: Disclosed are recombinant mutant Candida utilis uricase enzymes with improved pancreatin stability and/or activity, compositions containing such uricase enzymes, which can be used, among other things, to treat diseases or disorders associated with an elevated amount of uric acid, including, for example, hyperuricemia, hyperuricosuria, and gout.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: October 27, 2020
    Assignee: Allena Pharmaceuticals, Inc.
    Inventors: Aditi R. Deshpande, Danica Grujic, Sridhar Govindarajan, Mark Welch
  • RECOMBINANT URICASE ENZYME
    Publication number: 20200308534
    Abstract: Disclosed are recombinant mutant Candida utilis uricase enzymes with improved pancreatin stability and/or activity, compositions containing such uricase enzymes, which can be used, among other things, to treat diseases or disorders associated with an elevated amount of uric acid, including, for example, hyperuricemia, hyperuricosuria, and gout.
    Type: Application
    Filed: July 6, 2018
    Publication date: October 1, 2020
    Applicant: Allena Pharmaceuticals, Inc.
    Inventors: Aditi R. DESHPANDE, Danica GRUJIC, Sridhar GOVINDARAJAN, Mark WELCH
  • DNA VECTORS, TRANSPOSONS AND TRANSPOSASES FOR EUKARYOTIC GENOME MODIFICATION
    Publication number: 20200190524
    Abstract: The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.
    Type: Application
    Filed: December 23, 2019
    Publication date: June 18, 2020
    Applicant: DNA2.0, INC.
    Inventors: Jeremy Minshull, Mark Welch, Sridhar Govindrajan, Maggie Lee, Kate Caves, Jon Ness
  • RECOMBINANT URICASE ENZYME
    Publication number: 20200071681
    Abstract: Disclosed are recombinant mutant Candida utilis uricase enzymes with improved pancreatin stability and/or activity, compositions containing such uricase enzymes, which can be used, among other things, to treat diseases or disorders associated with an elevated amount of uric acid, including, for example, hyperuricemia, hyperuricosuria, and gout.
    Type: Application
    Filed: November 5, 2019
    Publication date: March 5, 2020
    Inventors: Aditi R. Deshpande, Danica Grujic, Sridhar Govindarajan, Mark Welch